NDC 66658-230

Synagis

Palivizumab

Synagis is a Intramuscular Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Swedish Orphan Biovitrum Ab (publ). The primary component is Palivizumab.

• Product ID: 66658-230_2f379d7b-dcfd-4629-b14c-2f1d37891f7e
• NDC: 66658-230
• Product Type: Human Prescription Drug
• Proprietary Name: Synagis
• Generic Name: Palivizumab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAMUSCULAR
• Marketing Start Date: 1999-12-09
• Marketing Category: BLA / BLA
• Application Number: BLA103770
• Labeler Name: Swedish Orphan Biovitrum AB (publ)
• Substance Name: PALIVIZUMAB
• Active Ingredient Strength: 50 mg/.5mL
• Pharm Classes: Antibodies, Monoclonal [CS], Fusion Protein Inhibitors [MoA], Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 66658-230-01

.5 mL in 1 VIAL, SINGLE-DOSE (66658-230-01)

• Marketing Start Date: 2005-09-28
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Synagis" or generic name "Palivizumab"

NDC	Brand Name	Generic Name
60574-4113	Synagis	palivizumab
60574-4114	Synagis	palivizumab
66658-230	Synagis	palivizumab
66658-231	Synagis	palivizumab